

# **Encephalitis Treatment Market Forecasts to 2032 – Global Analysis By Disease Type (Primary encephalitis and Secondary encephalitis), Route of Administration, Causative Agent, Distribution Channel, End User and By Geography**

<https://marketpublishers.com/r/E832672275DEEN.html>

Date: July 2025

Pages: 150

Price: US\$ 4,150.00 (Single User License)

ID: E832672275DEEN

## **Abstracts**

According to Statistics MRC, the Global Encephalitis Treatment Market is accounted for \$23.9 billion in 2025 and is expected to reach \$38.9 billion by 2032 growing at a CAGR of 7.2% during the forecast period. Encephalitis treatment refers to the medical management and therapeutic interventions used to address encephalitis, an inflammation of the brain typically caused by viral infections, though bacterial, fungal, or autoimmune causes are also possible. Treatment aims to reduce brain inflammation, manage symptoms, and prevent complications. It often includes antiviral or antibiotic medications, corticosteroids to reduce swelling, anticonvulsants for seizures, and supportive care such as hydration and oxygen therapy. In severe cases, hospitalization and intensive care may be necessary. Early diagnosis and prompt treatment are crucial to minimize long-term neurological damage and improve patient outcomes, especially in vulnerable populations such as children and the elderly.

According to the National Center for Vector Borne Diseases Control, Japanese encephalitis is a significant health concern in India.

Market Dynamics:

Driver:

Rising Incidence of Viral Encephalitis

The rising incidence of viral encephalitis is positively impacting the encephalitis treatment market by driving demand for advanced diagnostic tools, antiviral therapies, and supportive care solutions. Increasing awareness and early diagnosis are pushing healthcare providers to invest in better treatment protocols, boosting market growth. Moreover, governments and healthcare institutions are funding research and development efforts to improve treatment efficacy. This growing focus on timely and effective management of encephalitis is encouraging pharmaceutical companies to innovate, further expanding the market landscape.

Restraint:

### High Cost of Treatment

The high cost of encephalitis treatment significantly hampers market growth, especially in low- and middle-income regions. Expensive antiviral medications, intensive care, prolonged hospitalization, and rehabilitation services place a financial burden on patients and healthcare systems. This deters timely diagnosis and treatment, leading to delayed interventions and poor outcomes. As a result, the affordability barrier restricts access to advanced treatment options, limiting market expansion and posing a major challenge to healthcare providers.

Opportunity:

### Advancements in Diagnostics & Therapeutics

Advancements in diagnostics and therapeutics are significantly driving growth in the market. The development of rapid and accurate diagnostic tools enables early detection, improving treatment outcomes. Innovations in antiviral and immunomodulatory therapies are enhancing patient recovery rates and reducing long-term complications. Personalized medicine and biomarker-based treatments are further refining therapeutic approaches. These advancements not only improve clinical efficiency but also encourage greater investment in research, ultimately expanding the market and offering improved care for encephalitis patients globally.

Threat:

### Complex Diagnosis

The complex and time-consuming process of diagnosing encephalitis poses a

significant challenge to the treatment market. Delayed or inaccurate diagnosis can lead to postponed treatment, worsening patient outcomes and increasing the risk of complications. Limited access to advanced diagnostic tools, especially in low-resource settings, further hampers early detection. This complexity restricts market growth by increasing healthcare costs and deterring timely intervention, thereby impacting the overall effectiveness of encephalitis treatment solutions.

### Covid-19 Impact

The COVID-19 pandemic disrupted the encephalitis treatment market by straining healthcare systems and diverting resources toward managing the virus. Delays in diagnosis, reduced hospital visits, and interruptions in clinical trials affected timely treatment. However, increased awareness of neurological complications linked to COVID-19 also led to a renewed focus on encephalitis research. This dual impact created both short-term challenges and long-term opportunities for advancements in encephalitis diagnostics and therapies.

The viral segment is expected to be the largest during the forecast period

The viral segment is expected to account for the largest market share during the forecast period, due to rising prevalence of viral infections such as herpes simplex, Japanese encephalitis, and West Nile virus. Increasing awareness and early diagnosis of viral encephalitis have boosted the demand for effective antiviral drugs and supportive therapies. Moreover, government initiatives and funding for vaccination and outbreak control contribute to market expansion. The urgency to manage viral outbreaks further accelerates research, development, and adoption of advanced encephalitis treatment options.

The antibiotics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the antibiotics segment is predicted to witness the highest growth rate, as it offers effective solutions against bacterial causes of the disease, particularly in secondary encephalitis cases. Increased awareness among healthcare providers, advancements in targeted antibiotic therapies are driving demand. Additionally, the growing availability of broad-spectrum antibiotics and supportive diagnostic tools is enhancing timely treatment, reducing complications, and improving patient recovery rates. These factors collectively support market expansion and reinforce antibiotics as a critical component in encephalitis care strategies

### Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share owing to rising healthcare awareness, increasing prevalence of viral infections, and improved access to advanced medical facilities. Government initiatives aimed at strengthening healthcare infrastructure and expanding immunization programs are further supporting market expansion. Additionally, increasing investments in R&D and the availability of effective antiviral therapies are contributing to enhanced treatment outcomes. The growing population and demand for better neurological care are also fueling the region's market growth positively.

### Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, because of growing awareness and an increase in encephalitis cases brought on by viral infections and illnesses spread by mosquitoes. Drug development and early diagnosis have increased because to strong government initiatives and research funding. The area gains by having access to cutting-edge technologies and being home to significant pharmaceutical enterprises. Furthermore, the market is expanding in the US and Canada due to rising need for efficient antiviral treatments and vaccinations.

### Key players in the market

Some of the key players profiled in the Encephalitis Treatment Market include Pfizer Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Basilea Pharmaceutica Ltd., Melinta Therapeutics LLC, Bristol Myers Squibb, Novartis AG, Johnson & Johnson, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Pharma Limited, Hikma Pharmaceuticals PLC, Valneva SE, Bharat Biotech, BIKEN and Substiparm.

### Key Developments:

In May 2025, Pfizer Inc. announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc., for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

In October 2024, TRIANA Biomedicines, Inc. announced that it has entered into a strategic collaboration and licensing agreement with Pfizer to discover novel molecular glue degraders for multiple targets in several disease areas, including oncology.

#### Disease Types Covered:

Primary encephalitis

Secondary encephalitis

#### Treatments Covered:

Antiviral agents

Steroid injections

Antibiotics

Immunoglobulin therapy

Plasmapheresis

Other Treatments

#### Route of Administrations Covered:

Oral

Parenteral

Other Routes of Administration

#### Causative Agents Covered:

Viral

Autoimmune

Bacterial

Pathogens

Distribution Channels Covered:

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

End Users Covered:

Hospitals

Research Centers

Clinics

Specialty Centers

Other End Users

Regions Covered:

North America

US

Canada

Mexico

## Europe

Germany

UK

Italy

France

Spain

Rest of Europe

## Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

## South America

Argentina

Brazil

Chile

Rest of South America

## Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

### What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

### Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

#### Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

#### Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

### Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

## Contents

### **1 EXECUTIVE SUMMARY**

### **2 PREFACE**

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
  - 2.4.1 Data Mining
  - 2.4.2 Data Analysis
  - 2.4.3 Data Validation
  - 2.4.4 Research Approach
- 2.5 Research Sources
  - 2.5.1 Primary Research Sources
  - 2.5.2 Secondary Research Sources
  - 2.5.3 Assumptions

### **3 MARKET TREND ANALYSIS**

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19

### **4 PORTERS FIVE FORCE ANALYSIS**

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

### **5 GLOBAL ENCEPHALITIS TREATMENT MARKET, BY DISEASE TYPE**

*Encephalitis Treatment Market Forecasts to 2032 – Global Analysis By Disease Type (Primary encephalitis and Se...*

- 5.1 Introduction
- 5.2 Primary encephalitis
- 5.3 Secondary encephalitis

## **6 GLOBAL ENCEPHALITIS TREATMENT MARKET, BY TREATMENT**

- 6.1 Introduction
- 6.2 Antiviral agents
- 6.3 Steroid injections
- 6.4 Antibiotics
- 6.5 Immunoglobulin therapy
- 6.6 Plasmapheresis
- 6.7 Other Treatments

## **7 GLOBAL ENCEPHALITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION**

- 7.1 Introduction
- 7.2 Oral
- 7.3 Parenteral
- 7.4 Other Routes of Administration

## **8 GLOBAL ENCEPHALITIS TREATMENT MARKET, BY CAUSATIVE AGENT**

- 8.1 Introduction
- 8.2 Viral
- 8.3 Autoimmune
- 8.4 Bacterial
- 8.5 Pathogens

## **9 GLOBAL ENCEPHALITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL**

- 9.1 Introduction
- 9.2 Hospital Pharmacies
- 9.3 Online Pharmacies
- 9.4 Retail Pharmacies

## **10 GLOBAL ENCEPHALITIS TREATMENT MARKET, BY END USER**

- 10.1 Introduction
- 10.2 Hospitals
- 10.3 Research Centers
- 10.4 Clinics
- 10.5 Specialty Centers
- 10.6 Other End Users

## **11 GLOBAL ENCEPHALITIS TREATMENT MARKET, BY GEOGRAPHY**

- 11.1 Introduction
- 11.2 North America
  - 11.2.1 US
  - 11.2.2 Canada
  - 11.2.3 Mexico
- 11.3 Europe
  - 11.3.1 Germany
  - 11.3.2 UK
  - 11.3.3 Italy
  - 11.3.4 France
  - 11.3.5 Spain
  - 11.3.6 Rest of Europe
- 11.4 Asia Pacific
  - 11.4.1 Japan
  - 11.4.2 China
  - 11.4.3 India
  - 11.4.4 Australia
  - 11.4.5 New Zealand
  - 11.4.6 South Korea
  - 11.4.7 Rest of Asia Pacific
- 11.5 South America
  - 11.5.1 Argentina
  - 11.5.2 Brazil
  - 11.5.3 Chile
  - 11.5.4 Rest of South America
- 11.6 Middle East & Africa
  - 11.6.1 Saudi Arabia
  - 11.6.2 UAE
  - 11.6.3 Qatar

11.6.4 South Africa

11.6.5 Rest of Middle East & Africa

## **12 KEY DEVELOPMENTS**

12.1 Agreements, Partnerships, Collaborations and Joint Ventures

12.2 Acquisitions & Mergers

12.3 New Product Launch

12.4 Expansions

12.5 Other Key Strategies

## **13 COMPANY PROFILING**

13.1 Pfizer Inc.

13.2 Sanofi S.A.

13.3 F. Hoffmann-La Roche Ltd.

13.4 GlaxoSmithKline plc (GSK)

13.5 Merck & Co., Inc.

13.6 Teva Pharmaceutical Industries Ltd.

13.7 Abbott Laboratories

13.8 Basilea Pharmaceutica Ltd.

13.9 Melinta Therapeutics LLC

13.10 Bristol Myers Squibb

13.11 Novartis AG

13.12 Johnson & Johnson

13.13 Eli Lilly and Company

13.14 Takeda Pharmaceutical Company Limited

13.15 Aurobindo Pharma Limited

13.16 Hikma Pharmaceuticals PLC

13.17 Valneva SE

13.18 Bharat Biotech

13.19 BIKEN

13.20 Substipharm

## List Of Tables

### LIST OF TABLES

Table 1 Global Encephalitis Treatment Market Outlook, By Region (2024-2032) (\$MN)

Table 2 Global Encephalitis Treatment Market Outlook, By Disease Type (2024-2032) (\$MN)

Table 3 Global Encephalitis Treatment Market Outlook, By Primary encephalitis (2024-2032) (\$MN)

Table 4 Global Encephalitis Treatment Market Outlook, By Secondary encephalitis (2024-2032) (\$MN)

Table 5 Global Encephalitis Treatment Market Outlook, By Treatment (2024-2032) (\$MN)

Table 6 Global Encephalitis Treatment Market Outlook, By Antiviral agents (2024-2032) (\$MN)

Table 7 Global Encephalitis Treatment Market Outlook, By Steroid injections (2024-2032) (\$MN)

Table 8 Global Encephalitis Treatment Market Outlook, By Antibiotics (2024-2032) (\$MN)

Table 9 Global Encephalitis Treatment Market Outlook, By Immunoglobulin therapy (2024-2032) (\$MN)

Table 10 Global Encephalitis Treatment Market Outlook, By Plasmapheresis (2024-2032) (\$MN)

Table 11 Global Encephalitis Treatment Market Outlook, By Other Treatments (2024-2032) (\$MN)

Table 12 Global Encephalitis Treatment Market Outlook, By Route of Administration (2024-2032) (\$MN)

Table 13 Global Encephalitis Treatment Market Outlook, By Oral (2024-2032) (\$MN)

Table 14 Global Encephalitis Treatment Market Outlook, By Parenteral (2024-2032) (\$MN)

Table 15 Global Encephalitis Treatment Market Outlook, By Other routes of Administration (2024-2032) (\$MN)

Table 16 Global Encephalitis Treatment Market Outlook, By Causative Agent (2024-2032) (\$MN)

Table 17 Global Encephalitis Treatment Market Outlook, By Viral (2024-2032) (\$MN)

Table 18 Global Encephalitis Treatment Market Outlook, By Autoimmune (2024-2032) (\$MN)

Table 19 Global Encephalitis Treatment Market Outlook, By Bacterial (2024-2032) (\$MN)

Table 20 Global Encephalitis Treatment Market Outlook, By Other Pathogens (2024-2032) (\$MN)

Table 21 Global Encephalitis Treatment Market Outlook, By Distribution Channel (2024-2032) (\$MN)

Table 22 Global Encephalitis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) (\$MN)

Table 23 Global Encephalitis Treatment Market Outlook, By Online Pharmacies (2024-2032) (\$MN)

Table 24 Global Encephalitis Treatment Market Outlook, By Retail Pharmacies (2024-2032) (\$MN)

Table 25 Global Encephalitis Treatment Market Outlook, By End User (2024-2032) (\$MN)

Table 26 Global Encephalitis Treatment Market Outlook, By Hospitals (2024-2032) (\$MN)

Table 27 Global Encephalitis Treatment Market Outlook, By Research Centers (2024-2032) (\$MN)

Table 28 Global Encephalitis Treatment Market Outlook, By Clinics (2024-2032) (\$MN)

Table 29 Global Encephalitis Treatment Market Outlook, By Specialty Centers (2024-2032) (\$MN)

Table 30 Global Encephalitis Treatment Market Outlook, By Other End Users (2024-2032) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

## I would like to order

Product name: Encephalitis Treatment Market Forecasts to 2032 – Global Analysis By Disease Type (Primary encephalitis and Secondary encephalitis), Route of Administration, Causative Agent, Distribution Channel, End User and By Geography

Product link: <https://marketpublishers.com/r/E832672275DEEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E832672275DEEN.html>